PEOPLE - Changes at Quidel (US):
This article was originally published in Clinica
Quidel has announced that the following vice-presidents are leaving the company: Steven Burke, finance and administration; Glenn Holmes, marketing and sales; and Darryll Getzlaff, human resources. The US immunodiagnostics company has appointed Timothy Burke of Somatogen, a recombinant haemoglobin products developer, interim chief financial officer and Charles Bowden, a former vice-president of business development at Nellcor, has been named chief medical officer and vice-president of technology and business development.
You may also be interested in...
Celltrion has accelerated the development of its antiviral treatment for COVID-19 and aims to launch a rapid self-testing kit that could provide results within 15-20 minutes. The Korean firm also plans to develop a ‘super antibody’ to prepare for potential future pandemic situations.
Paracetamol, acetylcysteine and loperamide among list of OTC drugs deemed "essential" by Spain in the fight against coronavirus.
Mylan, in partnership with Indian firm Lupin, will be looking to rival Biogen and Sandoz by introducing an etanercept biosimilar in European markets following a positive opinion by the EMA’s CHMP on Mylan's application.